Becton, Dickinson and Company $BDX Shares Sold by AMI Asset Management Corp

AMI Asset Management Corp decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 9.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 270,526 shares of the medical instruments supplier's stock after selling 28,672 shares during the quarter. Becton, Dickinson and Company accounts for about 2.7% of AMI Asset Management Corp's holdings, making the stock its 18th biggest position. AMI Asset Management Corp owned about 0.09% of Becton, Dickinson and Company worth $46,598,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares in the last quarter. Versant Capital Management Inc increased its holdings in shares of Becton, Dickinson and Company by 27.4% during the 1st quarter. Versant Capital Management Inc now owns 265 shares of the medical instruments supplier's stock worth $61,000 after buying an additional 57 shares during the last quarter. NBC Securities Inc. acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth $102,000. Merit Financial Group LLC increased its holdings in shares of Becton, Dickinson and Company by 54.3% during the 1st quarter. Merit Financial Group LLC now owns 5,846 shares of the medical instruments supplier's stock worth $1,339,000 after buying an additional 2,058 shares during the last quarter. Finally, Whipplewood Advisors LLC increased its holdings in Becton, Dickinson and Company by 67.9% in the 1st quarter. Whipplewood Advisors LLC now owns 880 shares of the medical instruments supplier's stock valued at $202,000 after purchasing an additional 356 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,023 shares of company stock valued at $562,036 in the last three months. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $190.90 on Thursday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm's 50-day moving average price is $188.71 and its two-hundred day moving average price is $188.20. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The stock has a market capitalization of $54.72 billion, a P/E ratio of 34.33, a P/E/G ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. During the same quarter in the previous year, the company posted $3.50 earnings per share. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Analyst Ratings Changes

Several analysts recently issued reports on BDX shares. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a report on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 price target for the company. Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Piper Sandler reissued a "neutral" rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Morgan Stanley raised their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Finally, Wells Fargo & Company raised their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Three investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.